Californian biotech firm Gilead Sciences (Nasdaq: GILD) has received priority review status from the US FDA for an investigational combination of HIV candidate bictegravir plus emtricitabine/tenofovir alafenamide.
The combination of emtricitabine and tenofovir alafenamide, also a Gilead program and marketed as Descovy, received approval in the USA and Europe as a treatment for HIV in April last year.
A decision on the new triple therapy is expected by February 12, 2018.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze